Skip to main content

Table 2 Univariate and multivariate analyses of covariate effects on the modified Rodnan skin score (n = 1,070)

From: Effect of menopause on the modified Rodnan skin score in systemic sclerosis

Covariate Univariate effect estimate (95% CI) Multivariate effect estimate (95% CI)
Menopausal status   
 Premenopausal Reference Reference
 Postmenopausal −2.03 (−3.07, −0.99) −2.62 (−4.44, −0.80)
Disease subtype   
 Diffuse Reference Reference
 Limited −10.45 (−11.21, −9.69) −12.10 (−13.81, −10.39)
Menopause* disease typea 1.90 (0.06, 3.74) 2.04 (0.20, 3.88)
Time since baseline (years) −0.13 (−0.32, 0.06) 0.19 (0.04, 0.34)
Disease duration at baseline (years) −0.14 (−0.18, −0.10) −0.05 (−0.07, −0.03)
Age at disease onset (years) 0.04 (0.01, 0.07) 0.02 (−0.01, 0.05)
Race/ethnicity   
 White Reference Reference
 Black −2.00 (−9.96, 5.96) −4.6 (−10.11, 0.91)
 Other 0.66 (−0.73, 2.05) −0.46 (−1.42, 0.50)
Smoking   
 Never Reference Reference
 Ever −0.12 (−1.40, 1.16) −0.08 (−0.71, 0.55)
Oral contraceptive pill   
 Past/never Reference Reference
 Current −0.93 (−4.28, 2.42) −0.60 (−3.03, 1.83)
Hormone replacement therapy   
 Past/never Reference Reference
 Current −0.99 (−3.05, 1.07) −0.43 (−1.74, 0.88)
DMARDsb   
 Past/never Reference Reference
 Current 2.09 (0.94, 3.24) 1.08 (0.22, 1.94)
Cyclophosphamide   
 Never Reference Reference
 Ever 1.56 (−0.23, 3.35) 0.73 (−0.60, 2.06)
  1. aInteraction term between menopausal status and disease subtype. DMARDs, bdisease- modifying antirheumatic drugs.